Powder: -20°C for 3 years | In solvent: -80°C for 1 year
PRIMA-1 (NSC-281668) 是一种突变型 p53复活剂,可恢复 TP53 突变型甲状腺癌细胞对组蛋白甲基化抑制剂 3-Deazaneplanocin A 的敏感性。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 161 | 现货 | ||
5 mg | ¥ 369 | 现货 | ||
10 mg | ¥ 533 | 现货 | ||
25 mg | ¥ 987 | 现货 | ||
50 mg | ¥ 1,650 | 现货 | ||
100 mg | ¥ 2,560 | 现货 | ||
200 mg | ¥ 3,790 | 现货 | ||
500 mg | ¥ 5,900 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 397 | 现货 |
产品描述 | PRIMA-1 (NSC-281668) is a mutant p53 reactivator. It induces apoptosis and inhibits growth of human tumors with mutant p53. |
体外活性 | PRIMA-1 is converted to compounds that form adducts with thiols in mutant p53. Modification of thiol groups in mutant p53 by PRIMA-1 conversion products is sufficient to restore its tumor suppressor activity.[2]. PRIMA-1 inhibits the growth of pancreatic cancer cell lines and induces cell cycle arrest and decreases DNA synthesis. It selectively induces apoptosis and cell death in mutant p53-expressing pancreatic cancer cells and also leads to activation of p53-dependent apoptotic pathways. PRIMA-1 enhances the cytotoxicity of chemotherapeutic agents active against mutant p53 pancreatic cancer cells[1]. PRIMA-1 has antileukemic properties in acute promyelocytic leukemia-derived NB4 cells. PRIMA-1-triggered apoptosis is in a dose-dependent and time-dependent manner as indicated by the MTT assay and annexin-V staining. Apoptosis induction by PRIMA-1 is associated with caspase-9, caspase-7 activation and PARP cleavage. PRIMA-1 does not show any significant apoptotic effect in normal human peripheral blood mononuclear cells[4]. |
体内活性 | Intravenous (i.v.) injections of PRIMA-1 in mice does not cause any obvious changes in weight or behavior compared with untreated animals. PRIMA-1 has in vivo antitumor activity in this animal tumor model. It suppresses in vivo tumor growth in a mutant p53-dependent manner[3]. |
细胞实验 | Cells are kept at a temperature of 37 °C, a minimum relative humidity of 95 %, and an atmosphere of 5 % CO2 in air. Cell viability is measured by MTT assay after treatment with PRIMA-1. Briefly, cells are seeded in each well of 96-well plates in 100 μl culture medium and incubated overnight at 37 °C in an atmosphere of 5 % CO2. The next day, the medium is removed and cells washed with PBS and treated with vehicle control(DMSO, dimethylsulfoxide) or different concentrations of PRIMA-1 for 12 to 48 h; the medium is replaced with MTT solution diluted in medium once the treatment is completed. The plates are further incubated at 37 °C under 5 % CO2 for 4 h and then left at room temperature until completely dry. DMSO was then added and the absorbance is read at 492 nm using a microplate enzyme-linked immunoassay reader (ELISA). The relative growth activity is determined as the percentage absorbance of treated cells compared to that of vehicle treated cells (control).(Only for Reference) |
别名 | 2,2-Bis(hydroxymethyl)-3-quinuclidinone, NSC-281668, PRIMA 1 |
分子量 | 185.22 |
分子式 | C9H15NO3 |
CAS No. | 5608-24-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 35 mg/mL(189 mM)
H2O: 18.5 mg/mL(100 mM)
DMSO: 50 mg/mL (269.95 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / H2O / DMSO | 1 mM | 5.399 mL | 26.9949 mL | 53.9898 mL | 134.9746 mL |
5 mM | 1.0798 mL | 5.399 mL | 10.798 mL | 26.9949 mL | |
10 mM | 0.5399 mL | 2.6995 mL | 5.399 mL | 13.4975 mL | |
20 mM | 0.2699 mL | 1.3497 mL | 2.6995 mL | 6.7487 mL | |
50 mM | 0.108 mL | 0.5399 mL | 1.0798 mL | 2.6995 mL | |
100 mM | 0.054 mL | 0.2699 mL | 0.5399 mL | 1.3497 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
PRIMA-1 5608-24-2 Apoptosis Autophagy Others Ferroptosis NSC 281668 PRIMA1 2,2-Bis(hydroxymethyl)-3-quinuclidinone NSC-281668 inhibit MDM-2/p53 NSC281668 Inhibitor PRIMA 1 inhibitor